SCHEMBL5447455

SCHEMBL5447455

Cc1ccc(F)cc1NC(=O)Nc1sc2c(c1C(N)=O)CCOC2

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 2/20 0.58
ANO1 Q5XXA6 5/20 0.50
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
CXCR2 P25025 1/20 0.47
FLT3 P36888 3/20 0.45
MAPT P10636 2/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
ALDH1A1 P00352 1/20 0.45
GAA P10253 1/20 0.45
CNR2 P34972 2/20 0.44
CNR1 P21554 1/20 0.44
PTPRC P08575 1/20 0.43
PTPN2 P17706 1/20 0.43
PTPN1 P18031 1/20 0.43
PTPRB P23467 1/20 0.43
PTPRE P23469 1/20 0.43
EPHB4 P54760 1/20 0.43
KCNH2 Q12809 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5459139 0.90 CFTR (0.60) CFTRANO1NPC1RAB9AFLT3
SCHEMBL5455890 0.89 CFTR (0.59) CFTRANO1FLT3CNR2CNR1
SCHEMBL5455778 0.88 CFTR (0.55) CFTRANO1NPC1RAB9ACXCR2
SCHEMBL5457966 0.86 ANO1 (0.66) CFTRANO1NPC1RAB9ACXCR2
SCHEMBL5457889 0.85 CFTR (0.55) CFTRANO1NPC1RAB9AFLT3
SCHEMBL5461010 0.84 CFTR (0.58) CFTRANO1NPC1RAB9ACXCR2
SCHEMBL5457888 0.83 ANO1 (0.64) CFTRANO1NPC1RAB9ACXCR2
SCHEMBL5448389 0.83 CFTR (0.59) CFTRANO1FLT3MAPTMEN1
SCHEMBL5451228 0.83 CFTR (0.61) CFTRANO1NPC1RAB9ACXCR2
SCHEMBL5456340 0.82 CFTR (0.60) CFTRANO1NPC1RAB9ACXCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 CFTR 2030/4885ANO1 3245/4885NPC1 2627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.